{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:37:51Z","timestamp":1784932671616,"version":"3.55.0"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.semcancer.2020.06.013","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T09:26:23Z","timestamp":1592645183000},"page":"203-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin"],"prefix":"10.1016","volume":"79","author":[{"given":"Poupak","family":"Fallahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Martina","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Patrizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Rosaria","family":"Paparo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Marone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Galdiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Guglielmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudy","family":"Foddis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Cristaudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2020.06.013_bib0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-018-0866-1","article-title":"Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates","volume":"17","author":"Pstr\u0105g","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0010","unstructured":"NationalCancerInstitute. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/thyro.html."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0015","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ctrv.2015.06.002","article-title":"Targeted therapies in advanced differentiated thyroid cancer","volume":"41","author":"Carneiro","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0020","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer","volume":"19","author":"American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer","year":"2009","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0025","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0140-6736(03)12488-9","article-title":"Thyroid carcinoma","volume":"361","author":"Sherman","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0030","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/14737140.2016.1238764","article-title":"The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer","volume":"16","author":"Fallahi","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0035","first-page":"2306","article-title":"Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo","volume":"39","author":"Ferrari","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0040","first-page":"2225","article-title":"Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo","volume":"39","author":"Ferrari","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0045","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1365-2265.2008.03415.x","article-title":"Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells","volume":"70","author":"Antonelli","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0050","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2265.2008.03182.x","article-title":"Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests","volume":"69","author":"Antonelli","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0055","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1530\/EJE-08-0190","article-title":"Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration","volume":"159","author":"Antonelli","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0060","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/03007995.2017.1368466","article-title":"Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials","volume":"34","author":"Liu","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0065","first-page":"341","article-title":"Anaplastic thyroid cancer: prevalence, diagnosis and treatment","volume":"33","author":"Chiacchio","year":"2008","journal-title":"Minerva Endocrinol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/2251-6581-12-32","article-title":"Essential genes in thyroid cancers: focus on fascin","volume":"12","author":"Samimi","year":"2013","journal-title":"J. Diabetes Metab. Disord."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archsurg.133.1.89","article-title":"Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident","volume":"133","author":"Miccoli","year":"1998","journal-title":"Arch Surg"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0080","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/1574892813666180220110729","article-title":"Lenvatinib in the therapy of aggressive thyroid cancer: state of the art and new perspectives with patents recently applied","volume":"13","author":"Ferrari","year":"2018","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0085","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/105072503322021142","article-title":"Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer","volume":"13","author":"Antonelli","year":"2003","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0090","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.21037\/gs.2017.11.07","article-title":"Molecular testing in the diagnosis of differentiated thyroid carcinomas","volume":"7","author":"Ferrari","year":"2018","journal-title":"Gland Surg."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0095","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1089\/thy.2010.0332","article-title":"Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma","volume":"21","author":"Akaishi","year":"2011","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1245\/ASO.2006.05.042","article-title":"Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches","volume":"13","author":"Are","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0105","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ijrobp.2004.05.032","article-title":"Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy","volume":"60","author":"De Crevoisier","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0110","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/936285","article-title":"Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer","volume":"2014","author":"Pinto","year":"2014","journal-title":"J. Oncol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0115","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1089\/thy.2012.0302","article-title":"American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","volume":"22","author":"Smallridge","year":"2012","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0120","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2174\/0929867324666171006165942","article-title":"Sunitinib in the treatment of thyroid Cancer","volume":"26","author":"Ferrari","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0125","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrendo.2011.142","article-title":"Molecular genetics and diagnosis of thyroid cancer","volume":"7","author":"Nikiforov","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0130","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2174\/138920211798120808","article-title":"New targeted therapies for thyroid cancer","volume":"12","author":"Antonelli","year":"2011","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0135","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature05911","article-title":"Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls","volume":"447","author":"Wellcome Trust Case Control Consortium","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3803\/EnM.2018.33.2.175","article-title":"Genome-wide association studies of autoimmune thyroid diseases, thyroid function, and thyroid cancer","volume":"33","author":"Hwangbo","year":"2018","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0145","doi-asserted-by":"crossref","first-page":"E2084","DOI":"10.1210\/jc.2014-1734","article-title":"Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk","volume":"99","author":"Figlioli","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0150","doi-asserted-by":"crossref","first-page":"E1674","DOI":"10.1210\/jc.2013-1941","article-title":"Genome-wide association study on differentiated thyroid cancer","volume":"98","author":"Kohler","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0155","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/ng.1046","article-title":"Discovery of common variants associated with low TSH levels and thyroid cancer risk","volume":"44","author":"Gudmundsson","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0160","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ng.339","article-title":"Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations","volume":"41","author":"Gudmundsson","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0165","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12863-015-0180-5","article-title":"Common variants at the 9q22.33, 14q13.3 and ATM loci, and risk of differentiated thyroid cancer in the Cuban population","volume":"16","author":"Pereda","year":"2015","journal-title":"BMC Genet."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0170","first-page":"3160","article-title":"Association between XRCC1 and XRCC3 gene polymorphisms and risk of thyroid cancer","volume":"8","author":"Wang","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0175","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10689-015-9816-x","article-title":"Follicular variant of papillary thyroid cancer in Alstrom syndrome","volume":"14","author":"Papadakis","year":"2015","journal-title":"Fam. Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0180","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.7314\/APJCP.2013.14.11.6727","article-title":"Increased risk of differentiated thyroid carcinoma with combined effects of homologous recombination repair gene polymorphisms in an Iranian population","volume":"14","author":"Fayaz","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0185","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/jmedgenet-2011-100586","article-title":"Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24","volume":"49","author":"Jones","year":"2012","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0190","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/ijc.28483","article-title":"Contribution of ATM and FOXE1 (TTF2) to risk of papillary thyroid carcinoma in Belarusian children exposed to radiation","volume":"134","author":"Damiola","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0195","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1089\/thy.2013.0102","article-title":"Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma","volume":"23","author":"Liyanarachchi","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0200","doi-asserted-by":"crossref","first-page":"E1814","DOI":"10.1210\/jc.2012-1456","article-title":"Association of FOXE1 polyalanine repeat region with papillary thyroid cancer","volume":"97","author":"Bullock","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123700","article-title":"Common variants at 9q22.33, 14q13.3, and ATM loci, and risk of differentiated thyroid cancer in the French Polynesian population","volume":"10","author":"Maillard","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0210","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1093\/hmg\/ddq123","article-title":"The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl","volume":"19","author":"Takahashi","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000637","article-title":"The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1\/USF2 transcription factors","volume":"5","author":"Landa","year":"2009","journal-title":"PLoS Genet."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0220","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1089\/thy.2015.0665","article-title":"Papillary thyroid carcinoma: association between germline DNA variant markers and clinical parameters","volume":"26","author":"Jendrzejewski","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0225","doi-asserted-by":"crossref","first-page":"15966","DOI":"10.1038\/ncomms15966","article-title":"Genome-wide association and expression quantitative trait loci studies identify multiple susceptibility loci for thyroid cancer","volume":"8","author":"Son","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0230","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1210\/jc.2017-01798","article-title":"The role of NRG1 in the predisposition to papillary thyroid carcinoma","volume":"103","author":"He","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0235","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1158\/1078-0432.CCR-14-0854","article-title":"Molecular pathways: targeting NRG1 fusions in lung cancer","volume":"21","author":"Fernandez-Cuesta","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0240","doi-asserted-by":"crossref","first-page":"8922","DOI":"10.1038\/srep08922","article-title":"Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk","volume":"5","author":"Figlioli","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0245","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/ijc.29557","article-title":"Thyroid cancer GWAS identifies 10q26.12 and 6q14.1 as novel susceptibility loci and reveals genetic heterogeneity among populations","volume":"137","author":"Mancikova","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0250","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1002\/cncr.29038","article-title":"Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm\/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay","volume":"120","author":"Nikiforov","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0255","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1089\/thy.2015.0305","article-title":"Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance\/follicular lesion of undetermined significance cytology","volume":"25","author":"Nikiforov","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0260","doi-asserted-by":"crossref","first-page":"E1852","DOI":"10.1210\/jc.2013-2292","article-title":"Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer","volume":"98","author":"Nikiforova","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0265","doi-asserted-by":"crossref","first-page":"14517","DOI":"10.1038\/ncomms14517","article-title":"A genome-wide association study yields five novel thyroid cancer risk loci","volume":"8","author":"Gudmundsson","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0270","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.dnarep.2016.03.011","article-title":"Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma","volume":"41","author":"Cipollini","year":"2016","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0275","article-title":"Quantitative assessment of common genetic variants on FOXE1 and differentiated thyroid cancer risk","volume":"9","author":"Zhu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0280","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/thy.2017.0318","article-title":"Gene fusions in thyroid cancer","volume":"28","author":"Yakushina","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0285","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0290","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.29887","article-title":"NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States","volume":"122","author":"Prasad","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0295","doi-asserted-by":"crossref","first-page":"45784","DOI":"10.18632\/oncotarget.17412","article-title":"Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma","volume":"8","author":"Lu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0300","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0305","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2006-0017","article-title":"RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors","volume":"27","author":"de Groot","year":"2006","journal-title":"Endocr. Rev."},{"issue":"Suppl 2","key":"10.1016\/j.semcancer.2020.06.013_bib0310","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1038\/modpathol.2008.10","article-title":"Thyroid carcinoma: molecular pathways and therapeutic targets","volume":"21","author":"Nikiforov","year":"2008","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0315","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1530\/EJE-11-0499","article-title":"RET\/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint","volume":"165","author":"Marotta","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0320","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1210\/jc.2004-1426","article-title":"Challenging dogma in thyroid cancer molecular genetics--role of RET\/PTC and BRAF in tumor initiation","volume":"89","author":"Fagin","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0325","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.02289","article-title":"RET\/PTC activation in papillary thyroid carcinoma: european journal of endocrinology prize lecture","volume":"155","author":"Santoro","year":"2006","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0330","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11912-012-0217-0","article-title":"RET TKI: potential role in thyroid cancers","volume":"14","author":"Antonelli","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0335","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/erc.1.0978","article-title":"BRAF mutation in thyroid cancer","volume":"12","author":"Xing","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0340","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/cncr.27893","article-title":"RET\/PTC and PAX8\/PPARc chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics","volume":"119","author":"Leeman-Neill","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0345","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.jpedsurg.2004.06.016","article-title":"Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients \u226416 years old","volume":"39","author":"Spinelli","year":"2004","journal-title":"J. Pediatr. Surg."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0350","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s002689900132","article-title":"Epidemiologic and clinical evaluation of thyroid cancer in children from the Gomel region (Belarus)","volume":"20","author":"Antonelli","year":"1996","journal-title":"World J. Surg."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0355","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1089\/thy.2014.0067","article-title":"PAX8\/PPARc rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma","volume":"24","author":"Armstrong","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0360","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1210\/jc.2002-021907","article-title":"RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0365","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1210\/jc.2005-1336","article-title":"PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma","volume":"91","author":"Castro","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0370","first-page":"3947","article-title":"Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas","volume":"87","author":"Marques","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0375","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1073\/pnas.1321937111","article-title":"Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer","volume":"111","author":"Kelly","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087170","article-title":"Identification of a recurrent STRN\/ALK fusion in thyroid carcinomas","volume":"9","author":"Pe\u00b4rot","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0385","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1530\/ERC-14-0467","article-title":"Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer","volume":"22","author":"Park","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0390","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0395","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1210\/jc.2008-0273","article-title":"Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase\/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers","volume":"93","author":"Liu","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0400","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1677\/ERC-08-0154","article-title":"Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies","volume":"16","author":"Smallridge","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0405","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1634\/theoncologist.2013-0072","article-title":"RAS mutations in thyroid cancer","volume":"18","author":"Howell","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0410","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/gs.2019.10.18","article-title":"Novel treatments for anaplastic thyroid carcinoma","volume":"9","author":"Ferrari","year":"2020","journal-title":"Gland Surg."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0344-0338(00)80015-1","article-title":"Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin","volume":"196","author":"Motoi","year":"2000","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0420","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc3431","article-title":"Molecular pathogenesis and mechanisms of thyroid cancer","volume":"13","author":"Xing","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0425","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1517\/14656566.2013.796931","article-title":"Targeted therapy with kinase inhibitors in aggressive endocrine tumors","volume":"14","author":"Marotta","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0430","article-title":"Angiogenesis-inhibitors for metastatic thyroid cancer","volume":"3","author":"Tan","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0435","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0002-9440(10)65515-0","article-title":"Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features","volume":"155","author":"Bunone","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0440","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1067\/msy.2001.112592","article-title":"Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer","volume":"129","author":"Lennard","year":"2001","journal-title":"Surgery"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0445","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijrobp.2003.11.041","article-title":"Review of epidermal growth factor receptor biology","volume":"59","author":"Herbst","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0450","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1089\/thy.2011.2111.ed","article-title":"Does the epidermal growth factor receptor play a role in the progression of thyroid cancer?","volume":"21","author":"Knauf","year":"2011","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0455","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0460","article-title":"Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0465","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1476-4598-13-62","article-title":"Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer","volume":"13","author":"Morrison","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0470","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.21073","article-title":"Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations","volume":"103","author":"Quiros","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0475","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5808\/GI.2013.11.2.68","article-title":"Recent progress of genome study for anaplastic thyroid Cancer","volume":"11","author":"Lee","year":"2013","journal-title":"Genomics Inform."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0480","doi-asserted-by":"crossref","first-page":"6965","DOI":"10.2147\/OTT.S116594","article-title":"Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis","volume":"9","author":"Su","year":"2016","journal-title":"Onco. Ther."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0485","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1089\/thy.2010.1646","article-title":"Genetic alterations in the phosphatidylinositol-3 kinase\/Akt pathway in thyroid cancer","volume":"20","author":"Xing","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0490","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrg1656","article-title":"Telomeres and human disease: ageing, cancer and beyond","volume":"6","author":"Blasco","year":"2005","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0495","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/ERC-15-0533","article-title":"TERT promoter mutations in thyroid cancer","volume":"23","author":"Liu","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0500","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13000-016-0458-6","article-title":"Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation","volume":"11","author":"Bae","year":"2016","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0505","doi-asserted-by":"crossref","first-page":"298","DOI":"10.21037\/gs.2019.05.05","article-title":"Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up","volume":"8","author":"Antonelli","year":"2019","journal-title":"Gland Surg."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0510","first-page":"235","article-title":"Personalized treatment options for thyroid cancer: current perspectives","volume":"12","author":"Khatami","year":"2019","journal-title":"Pers. Med."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0515","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.bcp.2010.05.003","article-title":"Targeted therapy of thyroid cancer","volume":"80","author":"Sherman","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0520","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40259-013-0049-y","article-title":"Sorafenib and thyroid cancer","volume":"27","author":"Fallahi","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0525","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0530","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1089\/thy.2015.0518","article-title":"Primary cell culture systems for human thyroid studies","volume":"26","author":"Wang","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0535","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1210\/jc.2008-1102","article-title":"Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification","volume":"93","author":"Schweppe","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0540","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1089\/thy.2009.0195","article-title":"Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer","volume":"19","author":"Pilli","year":"2009","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0545","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1210\/jc.2005-2845","article-title":"An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET\/papillary thyroid cancer kinases","volume":"91","author":"Kim","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0550","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1089\/thy.2010.0008","article-title":"Sunitinib inhibits MEK\/ERK and SAPK\/JNK pathways and increases sodium\/iodide symporter expression in papillary thyroid cancer","volume":"20","author":"Fenton","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0555","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/cbt.12.5.16303","article-title":"Sunitinib inhibits papillary thyroid carcinoma with RET\/PTC rearrangement but not BRAF mutation","volume":"12","author":"Jeong","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0560","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1089\/thy.2011.0060","article-title":"Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells","volume":"22","author":"D\u2019Agostino","year":"2012","journal-title":"Thyroid."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0565","doi-asserted-by":"crossref","first-page":"E898","DOI":"10.1210\/jc.2011-3269","article-title":"Activation of the RAS\/RAF\/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines","volume":"97","author":"Piscazzi","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0570","doi-asserted-by":"crossref","first-page":"E1465","DOI":"10.1210\/jc.2013-1364","article-title":"Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1\/2 phosphorylation and by down-regulation of cyclin-D1","volume":"98","author":"Di Desidero","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0575","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canlet.2017.09.032","article-title":"Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer","volume":"411","author":"Di Desidero","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0580","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1358\/dot.2005.41.12.937959","article-title":"Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment","volume":"41","author":"Strumberg","year":"2005","journal-title":"Drugs Today"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0585","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djj069","article-title":"BAY 43-9006 inhibition of oncogenic RET mutants","volume":"98","author":"Carlomagno","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0590","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1507\/endocrj.EJ16-0525","article-title":"Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells","volume":"64","author":"Sawa","year":"2017","journal-title":"Endocr. J."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0595","first-page":"711","article-title":"Inhibition of autophagy enhances the targeted therapeutic effect of sorafenib in thyroid cancer","volume":"39","author":"Yi","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0600","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fendo.2015.00176","article-title":"Molecular targeted therapies of aggressive thyroid cancer","volume":"6","author":"Ferrari","year":"2015","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0605","doi-asserted-by":"crossref","first-page":"E288","DOI":"10.1210\/jc.2010-1905","article-title":"Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer","volume":"96","author":"Antonelli","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0610","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bcp.2011.03.022","article-title":"Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells","volume":"81","author":"Bocci","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0615","doi-asserted-by":"crossref","first-page":"E572","DOI":"10.1210\/jc.2013-2321","article-title":"CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo","volume":"99","author":"Antonelli","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0620","doi-asserted-by":"crossref","first-page":"E528","DOI":"10.1210\/jc.2011-1987","article-title":"CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo","volume":"97","author":"Antonelli","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0625","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12020-015-0717-4","article-title":"CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation","volume":"53","author":"Fallahi","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0630","first-page":"1077","article-title":"The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0635","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/jc.2002-021278","article-title":"Efficient inhibition of RET\/papillary thyroid carcinoma oncogenic kinases by 4 amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d] pyrimidine (PP2)","volume":"88","author":"Carlomagno","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0640","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1074\/jbc.271.2.695","article-title":"Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation","volume":"271","author":"Hanke","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0645","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1158\/1078-0432.CCR-12-0411","article-title":"Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary","volume":"18","author":"Thornton","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0650","doi-asserted-by":"crossref","first-page":"E991","DOI":"10.1210\/jc.2010-2381","article-title":"The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells","volume":"96","author":"Verbeek","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0655","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijscr.2016.06.013","article-title":"Individualized multimodal treatment strategy for anaplastic thyroid carcinoma-case report of long-term remission and review of literature","volume":"25","author":"Eckhardt","year":"2016","journal-title":"Int. J. Surg. Case Rep."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0660","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"Okamoto","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0665","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/638747","article-title":"Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models","volume":"2014","author":"Tohyama","year":"2014","journal-title":"J. Thyroid Res."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0670","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neo.2017.12.003","article-title":"Anti-cancer effects of HNHA and lenvatinib by the suppression of EMT-mediated drug resistance in cancer stem cells","volume":"20","author":"Lee","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0675","first-page":"903","article-title":"Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer","volume":"7","author":"Jing","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0680","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1517\/14656566.2015.981526","article-title":"Apatinib for the treatment of gastric cancer","volume":"16","author":"Geng","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0685","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1159\/000485583","article-title":"Apatinib inhibits angiogenesis via suppressing Akt\/GSK3\u03b2\/ANG signaling pathway in anaplastic thyroid cancer","volume":"44","author":"Jin","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0690","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0695","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/s41419-018-1054-3","article-title":"Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer","volume":"9","author":"Feng","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0700","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3803\/EnM.2018.33.1.121","article-title":"Combined effects of Baicalein and docetaxel on apoptosis in 8505c anaplastic thyroid Cancer cells via downregulation of the ERK and Akt\/mTOR pathways","volume":"33","author":"Park","year":"2018","journal-title":"Endocrinol. Metab. Seoul (Seoul)"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0705","doi-asserted-by":"crossref","first-page":"39702","DOI":"10.18632\/oncotarget.4052","article-title":"mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib","volume":"6","author":"Hanly","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0710","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1210\/jc.2016-1999","article-title":"Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib","volume":"102","author":"Wang","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0715","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/ERC-17-0182","article-title":"Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo","volume":"25","author":"Tsumagari","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0720","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1159\/000493296","article-title":"S100A4 knockout sensitizes anaplastic thyroid carcinoma cells harboring BRAFV600E\/Mt to vemurafenib","volume":"49","author":"Jiao","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0725","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0730","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2340\/00015555-2035","article-title":"Metastatic melanoma - a review of current and future treatment options","volume":"95","author":"Maverakis","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0735","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.3892\/ijo.2016.3723","article-title":"Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells","volume":"49","author":"Kurata","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0740","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.surg.2019.04.076","article-title":"Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro","volume":"167","author":"Ullmann","year":"2020","journal-title":"Surgery"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0745","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1089\/omi.2019.0050","article-title":"Toward in vitro epigenetic drug design for thyroid Cancer: the promise of PF-03814735, an Aurora kinase inhibitor","volume":"23","author":"Dalva-Aydemir","year":"2019","journal-title":"OMICS"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0750","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1470-2045(04)01509-8","article-title":"Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists","volume":"5","author":"Grommes","year":"2004","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0755","first-page":"2170","article-title":"Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells","volume":"86","author":"Ohta","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0760","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1677\/erc.1.00973","article-title":"Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture","volume":"12","author":"Fr\u00f6hlich","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0765","first-page":"89","article-title":"Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma","volume":"24","author":"Hayashi","year":"2004","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0770","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1210\/en.2005-1610","article-title":"Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells","volume":"147","author":"Aiello","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0775","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1158\/0008-5472.CAN-08-3718","article-title":"Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth","volume":"69","author":"Marlow","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0780","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0785","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1158\/1078-0432.CCR-06-0367","article-title":"Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo","volume":"12","author":"Luong","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0790","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.18632\/oncotarget.3268","article-title":"Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0795","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.omto.2019.01.007","article-title":"MAPK inhibitors enhance HDAC inhibitor-induced redifferentiation in papillary thyroid cancer cells harboring BRAF V600E: an in vitro study","volume":"12","author":"Fu","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0800","first-page":"200","article-title":"Precision medicine approach to anaplastic thyroid cancer: advances in targeted drug therapy based on specific signaling pathways","volume":"55","author":"Samimi","year":"2017","journal-title":"Acta Med. Iran."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0805","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/23808993.2019.1565940","article-title":"Recent advances in precision medicine for the treatment of anaplastic thyroid cancer","volume":"4","author":"Ferrari","year":"2019","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0810","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1054\/bjoc.2001.1797","article-title":"Flasks, fibres and flanks--pre-clinical tumour models for predicting clinical antitumour activity","volume":"84","author":"Newell","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0815","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/0277-5379(90)90165-P","article-title":"Validation of clinical predictive value of in vitro colorimetric chemosensitivity assay in head and neck cancer","volume":"26","author":"Schroyens","year":"1990","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.semcancer.2020.06.013_bib0820","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF02686104","article-title":"Methods and goals for the use of in vitro and in vivo chemosensitivity testing","volume":"35","author":"Blumenthal","year":"2007","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.semcancer.2020.06.013_bib0825","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3389\/fendo.2018.00764","article-title":"Antineoplastic effect of lenvatinib and vandetanib in primary anaplastic thyroid Cancer cells obtained from biopsy or fine needle aspiration","volume":"9","author":"Ferrari","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X20301498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X20301498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:51:45Z","timestamp":1760917905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X20301498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":165,"alternative-id":["S1044579X20301498"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2020.06.013","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2020.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}